Literature DB >> 27743202

Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria.

Andre Arizpe1, Kelly R Reveles1,2, Shrina D Patel3, Samuel L Aitken4,5.   

Abstract

Resistance to cephalosporins is now common among Gram-negative bacterial infections, including those caused by the Enterobacteriaceae and Pseudomonas aeruginosa, posing a major threat to public health. As resistance to the traditional drugs of choice for these infections, carbapenems, has also become increasingly common, interest in cefepime and piperacillin-tazobactam as carbapenem-sparing alternatives has increased. Additionally, the availability of the novel β-lactam-β-lactamase inhibitor combinations ceftolozane-tazobactam and ceftazidime-avibactam has added to the antimicrobial armamentarium available to treat these multidrug-resistant infections. Here, we review the recent literature on the use of carbapenem-sparing alternatives and highlight the potential utility of novel antimicrobials.

Entities:  

Keywords:  Carbapenem; Cefepime; Ceftazidime-avibactam; Ceftolozane-tazobactam; Extended-spectrum β-lactamase; Piperacillin-tazobactam; Pseudomonas aeruginosa

Year:  2016        PMID: 27743202     DOI: 10.1007/s11908-016-0552-7

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  101 in total

1.  Evaluation of MicroScan WalkAway and Vitek 2 for determination of the susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates to cefepime, cefotaxime and ceftazidime.

Authors:  Woori Jang; Yeon-Joon Park; Kang Gyun Park; Jinkyung Yu
Journal:  J Antimicrob Chemother       Date:  2013-05-12       Impact factor: 5.790

2.  Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration.

Authors:  Joseph L Kuti; Islam M Ghazi; Richard Quintiliani; Eric Shore; David P Nicolau
Journal:  Int J Antimicrob Agents       Date:  2016-07-08       Impact factor: 5.283

3.  Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia.

Authors:  Gary Wu; Teena Abraham; Spencer Lee
Journal:  Clin Infect Dis       Date:  2016-07-17       Impact factor: 9.079

4.  Combination treatment with extended-infusion ceftazidime/avibactam for a KPC-3-producing Klebsiella pneumoniae bacteraemia in a kidney and pancreas transplant patient.

Authors:  David M Jacobs; Sara DiTursi; Christine Ruh; Rajnikant Sharma; Jonathan Claus; Rashmi Banjade; Gauri G Rao
Journal:  Int J Antimicrob Agents       Date:  2016-06-23       Impact factor: 5.283

Review 5.  β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?

Authors:  Patrick N A Harris; Paul A Tambyah; David L Paterson
Journal:  Lancet Infect Dis       Date:  2015-02-23       Impact factor: 25.071

6.  Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.

Authors:  Stephen B Vickery; David McClain; Kurt A Wargo
Journal:  Pharmacotherapy       Date:  2016-09-01       Impact factor: 4.705

7.  Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.

Authors:  Andrew J Denisuik; Philippe R S Lagacé-Wiens; Johann D Pitout; Michael R Mulvey; Patricia J Simner; Franil Tailor; James A Karlowsky; Daryl J Hoban; Heather J Adam; George G Zhanel
Journal:  J Antimicrob Chemother       Date:  2013-05       Impact factor: 5.790

8.  Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study.

Authors:  G Zanetti; F Bally; G Greub; J Garbino; T Kinge; D Lew; J-A Romand; J Bille; D Aymon; L Stratchounski; L Krawczyk; E Rubinstein; M-D Schaller; R Chiolero; M-P Glauser; A Cometta
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

Review 9.  AmpC beta-lactamases.

Authors:  George A Jacoby
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

10.  Successful Treatment of Multi-Drug Resistant Pseudomonas aeruginosa Bacteremia with the Recommended Renally Adjusted Ceftolozane/Tazobactam Regimen.

Authors:  Ursula C Patel; David P Nicolau; Rabeeya K Sabzwari
Journal:  Infect Dis Ther       Date:  2016-03-02
View more
  5 in total

1.  Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Escherichia coli in Patients with Hematologic Malignancy.

Authors:  Grace E Benanti; Anne Rain T Brown; Terri Lynn Shigle; Jeffrey J Tarrand; Micah M Bhatti; Patrick M McDaneld; Samuel A Shelburne; Samuel L Aitken
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 2.  Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.

Authors:  Matt Shirley
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

3.  Emergence of bla OXA-1- and mph(A)-Producing Vibrio furnissii Isolated from Hospital Sewage.

Authors:  Haishan Mo; Xu Lin; Ming Liu; Hui Liang
Journal:  Infect Drug Resist       Date:  2022-06-18       Impact factor: 4.177

4.  An antibiotic stewardship exercise in the ICU: building a treatment algorithm for the management of ventilator-associated pneumonia based on local epidemiology and the 2016 Infectious Diseases Society of America/American Thoracic Society guidelines.

Authors:  Lyn S Awad; Dania I Abdallah; Anas M Mugharbil; Tamima H Jisr; Nabila S Droubi; Nabila A El-Rajab; Rima A Moghnieh
Journal:  Infect Drug Resist       Date:  2017-12-22       Impact factor: 4.003

5.  Ecological effects of cefepime use during antibiotic cycling on the Gram-negative enteric flora of ICU patients.

Authors:  Carola Venturini; Andrew N Ginn; Brooke E Wilson; Guy Tsafnat; Ian Paulsen; Sally R Partridge; Jonathan R Iredell
Journal:  Intensive Care Med Exp       Date:  2018-07-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.